Abstract
BackgroundRivaroxaban, a direct Factor Xa inhibitor, has been shown to be more effective in preventing venous thromboembolism than enoxaparin regimens, with a similar safety profile, in patients undergoing hip or...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Hospital Pharmacy: Science and Practice
Paper Title
Journal
Date
